Sunday (27.10.2024)

08:00 – 09:30

Room: Großer Saal

Scientific Session Pediatric and Adolescent Treatment Concepts

  • Jonathan Friedberg
  • Christine Mauz-Körholz
  • 08:00–08:20

    Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

    • Sharon Castellino
  • 08:20–08:40

    Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

    • Christine Mauz-Körholz
  • 08:40–09:00

    Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

    • Jamie Flerlage
    • Kara Kelly
  • 09:00–09:10

    EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

    • Dieter Körholz
  • 09:10–09:20

    Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

    • Sharon Castellino
  • 09:20–09:30

    Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

    • Kara Kelly

10:00 – 11:30

Room: Großer Saal

Scientific Session Biology & Microenvironment

  • Sirpa Leppä
  • Margaret Shipp
  • 10:00–10:25

    Pathogenesis of HL

    • Ralf Küppers
  • 10:25–10:50

    Multimodal characterization of cHL

    • Christian Steidl
  • 10:50–11:00

    Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

    • Kristiina Karihtala
  • 11:00–11:10

    Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

    • Michel Heger
  • 11:10–11:20

    Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

    • Michael Binkley
  • 11:20–11:30

    Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

    • Tomohiro Aoki

12:00 – 13:30

Room: Großer Saal

Satellite Symposium (by MSD Sharp & Dohme GmbH) New concepts for the treatment of B-cell lymphomas

  • Peter Borchmann
  • 12:00–12:30

    B-cell lymphoma pathology – illustrated for non- pathologists

    • Wolfram Klapper
  • 12:30–13:00

    Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

    • Peter Borchmann
  • 13:00–13:30

    Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

    • Sascha Dietrich

14:00 – 15:30

Room: Großer Saal

Scientific Session Older Patients

  • Paul J. Bröckelmann
  • Andrew Evens
  • 14:00–14:25

    Implementing Frailty Assessment for Treatment Guidance in HL

    • Sarah Rutherford
  • 14:25–14:50

    Optimal Use of Targeted Agents to Address Unmet Need in Older HL

    • Graham Collins
  • 14:50–15:00

    A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

    • Kjersti Lia
  • 15:00–15:10

    Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

    • Aisling Barrett
  • 15:10–15:20

    Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

    • Justin Ferdinandus
  • 15:20–15:30

    Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

    • Sarah Rutherford

16:00 – 17:30

Room: Großer Saal

Satellite Symposium (by Takeda Pharmaceuticals USA, Inc.) Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma

  • John Radford
  • 16:00–16:05

    Welcome and introduction

  • 16:05–16:15

    Spotlight on ECHELON-1: 7-year survival data

    • John Radford
  • 16:15–16:45

    Real-world insights: frontline treatment of stages III & IV cHL

    • Chiara Rusconi
  • 16:45–17:00

    Q&A

  • 17:00–17:25

    cHL in the real-world: a case study approach

    • Carolina Valeria Mahuad
    • John Radford

18:00 – 19:30

Room: Großer Saal

Scientific Session Advanced Stages

  • Alex Herrera
  • Josée Zijlstra
  • 18:00–18:25

    Individualized treatment de-escalation improves overall outcomes

    • Peter Borchmann
  • 18:25–18:50

    Immune-chemotherapy overcomes the need for individualization

    • Jonathan Friedberg
  • 18:50–19:00

    2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

    • Alex Herrera
  • 19:00–19:10

    Development and application of a validated MRD assay in Hodgkin Lymphoma

    • Julia Mattlener
  • 19:10–19:20

    EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

    • Martin Hutchings
  • 19:20–19:30

    Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

    • Justin Ferdinandus

ISHL13 Program at a Glance (PDF)

ISHL13 Program at a Glance (PDF)

ISHL13 Final Program

ISHL13 Final Program

Save the date

Save the event to your calendar

Archive

You can explore the ISHL12 program to get an impression of the broad spectrum and diversity of the congress.